Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963226 | 0.92 | PARP10 (0.60) | PARP10KMT2AHPGDCTNNB1TSHR | |
| Diphenyl Ethanedioat SCHEMBL43364 | 0.85 | TDP1 (0.54) | TDP1L3MBTL1ATMHSD17B10HPGD | |
| Diphenyl Ethanedioat SCHEMBL2254079 | 0.84 | PARP10 (0.46) | PARP10TDP1L3MBTL1ATMMEN1 | |
| Diphenyl Ethanedioat SCHEMBL27328178 | 0.82 | TDP1 (0.52) | TDP1L3MBTL1ATMHSD17B10HPGD | |
| SCHEMBL27505259 | 0.82 | ELANE (0.49) | PARP10TDP1L3MBTL1ATMMEN1 | |
| SCHEMBL419381 | 0.80 | TDP1 (0.50) | TDP1L3MBTL1ATMHSD17B10HPGD | |
| Carbamic Acid Phenyl Ester SCHEMBL7566 | 0.80 | MEN1 (0.70) | PARP10TDP1L3MBTL1ATMMEN1 | |
| SCHEMBL131450 | 0.80 | TDP1 (0.50) | TDP1L3MBTL1ATMMEN1KMT2A | |
| Diphenyl Ethanedioat SCHEMBL10797780 | 0.80 | TDP1 (0.50) | TDP1L3MBTL1ATMHSD17B10HPGD | |
| SCHEMBL28242447 | 0.79 | TDP1 (0.50) | PARP10TDP1L3MBTL1ATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003920-A | Aligning agent for liquid crystal, the manufacturing method of liquid crystal orientation film and liquid crystal display element | 奇美实业股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-107987017-B | - 2 (1H)-quinolinones compound of a kind of 3,4-dihydro and the preparation method and application thereof | 绍兴文理学院 | 2019-07-12 | — | — | CN | disclosed |
| CN-108047133-B | A kind of preparation method of quinolinones compound | 绍兴文理学院 | 2019-07-12 | — | — | CN | disclosed |
| CN-109705022-A | A kind of preparation method of aromatic amine intermediate | 上海彩迩文生化科技有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108047133-A | A kind of preparation method of quinolinones compound | 绍兴文理学院 | 2018-05-18 | — | — | CN | disclosed |
| CN-107987017-A | A kind of 3,4-dihydro-2 (1H)-quinolinones compound and preparation method and application | 绍兴文理学院 | 2018-05-04 | — | — | CN | disclosed |
| US-9268915-B2 | Systems and methods for diagnosis or treatment | THERANOS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20130079599-A1 | SYSTEMS AND METHODS FOR DIAGNOSIS OR TREATMENT | Theranos, Inc., a Delaware Corporation (US) | 2013-03-28 | — | — | US | disclosed |
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2005028502-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| CN-1178922-C | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | - | 2004-12-08 | — | — | CN | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| CN-1430610-A | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-07-16 | — | — | CN | disclosed |
| EP-1289965-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| WO-2001090081-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| EP-0097942-B1 | ANTIALLERGIC PYRAZINE-BIS(2-OXOGLYCINE) COMPOUNDS | THE DOW CHEMICAL COMPANY (US) | 1987-07-22 | — | — | EP | disclosed |
| EP-0097942-A1 | Antiallergic pyrazine-bis(2-oxoglycine) compounds | THE DOW CHEMICAL COMPANY (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | PARP10 2468/4885TDP1 4153/4885L3MBTL1 2437/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | PARP10 2824/4885TDP1 3835/4885L3MBTL1 2339/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | PARP10 2824/4885TDP1 3835/4885L3MBTL1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.